853910-50-6

Basic information

• Product Name: Benzeneacetonitrile, 4-amino-2-cyano-
• Synonyms: Benzeneacetonitrile, 4-amino-2-cyano-
• CAS NO: 853910-50-6
• Molecular Formula: C₉H₇N₃
• Molecular Weight: 157.17
• Mol File: 853910-50-6.mol

Chemical Properties

• Boiling Point: 384.7±27.0 °C(Predicted)
• Appearance: /
• Density: 1.20±0.1 g/cm3(Predicted)
• PKA: 2.43±0.10(Predicted)
• CAS DataBase Reference: Benzeneacetonitrile, 4-amino-2-cyano-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, 4-amino-2-cyano-(853910-50-6)
• EPA Substance Registry System: Benzeneacetonitrile, 4-amino-2-cyano-(853910-50-6)

Safety Data

• Hazardous Substances Data: 853910-50-6(Hazardous Substances Data)

Upstream product

• 90484-04-1 (2-Cyano-4-nitro-phenyl)-acetonitrile 
• 3759-28-2 (2-cyanophenyl)acetonitrile 

Relevant articles and documents

Reductive domino reaction to access chromeno[2,3-c]isoquinoline-5-amines with antiproliferative activities against human tumor cells

An interaction of homophthalonitrile with salicylaldehydes proceeds as a novel domino reaction and results in the formation of nineteen 12H-chromeno[2,3-c]isoquinoline-5-amine derivatives. Four new bonds and two cycles are forged in a single synthetic operation, employing cheap and eco-friendly ammonium formate, acting both as a catalyst and a reducing agent. The in vitro cytotoxicity tests revealed antiproliferative activities against five human tumor cell lines, including the cisplatin-resistant ovarian carcinoma one (A2780cp8), with inhibitory potency data (IC50) in the low micromolar range in most cases. Molecular docking calculations and fluorescence quenching studies revealed possible binding properties with DNA of the active compounds.

1H-IMIDAZO[4,5-C]QUINOLINE DERIVATIVES IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of imidazoquinolines and salts thereof in the treatment of protein kinase diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, imidazoquinolines for use in the treatment of protein kinase dependent diseases, a method of treatment against said diseases, comprising administering the imidazoquinolines to a warm-blooded animal, especially a human, pharmaceutical preparations comprising an imidazoquinoline, especially for the treatment of a protein kinase dependent disease, novel imidazoquinolines, and a process for the preparation of the novel imidazoquinolines.